Alembic Pharmaceuticals Ltd shares have dipped 8 per cent to Rs 840 on the BSE in intra-day trade on Tuesday after the company reported disappointing numbers for the quarter ended June 2021 (Q1FY22), with consolidated profit after tax (PAT) declining 45.4 per cent year-on-year (YoY) to Rs 164.50 crore on the weak performance of US business. The pharmaceutical company had posted a PAT of Rs 301 crore in Q1FY21. Ebitda (earnings before interest, taxes, depreciation, and amortization) margins declined 1,258 basis points (bps) YoY to 17.8 per cent due to higher other expenditure.

The company’s revenues declined 1.1 per cent YoY to Rs 1,326 crore, with solid growth in domestic formulations being offset by a 38.1 per cent YoY deny in US sales to Rs 369 crore. Domestic formulations grew 57.2 per cent YoY to Rs 481 crore. The acute and specialty segments grew faster than the represented pharmaceutical market, the company said.

• NTPC Green Energy Adds 50 MW Solar Power in Rajasthan
• Coffee Day Enterprises Settles Rs 25 Cr Loan With Kemfin
• GST Collections Rise 14.7% to Rs 2.04 Lakh Crore in September
• GPT Infraprojects Bags Rs 385 Cr South Africa Rail Order
• Cabinet Backs Rs 1.86 Lakh Cr Plan for Green Power Grid

“India business grew exceptionally well and outpaced the industry, and we hope to see this momentum continuing due to the initiatives undertaken recently,” the management said. The US business faced price erosion due to increased competition; however, the long-term view of the US market remains intact, it added.

Stock Covered in the news

Alembic Pharmaceuticals Ltd-View Detailed Analysis